TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

CLASS ACTION UPDATE for SPPI, NBEVQ and IBM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE 25-Jan-2023 5:31 PM

NEW YORK, NY / ACCESSWIRE / January 25, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35946&wire=1
NBEVQ Shareholders Click Here: https://www.zlk.com/pslra-1/newage-class-action-submission-form?prid=35946&wire=1
IBM Shareholders Click Here: https://www.zlk.com/pslra-1/ibm-class-action-submission-form?prid=35946&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, January 25, 2023, Press release picture

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline: February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35946&wire=1

According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.

NewAge, Inc. (OTC:NBEVQ)

NBEVQ Lawsuit on behalf of: investors who purchased January 18, 2018 - October 18, 2022
Lead Plaintiff Deadline: February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/newage-class-action-submission-form?prid=35946&wire=1

According to the filed complaint, during the class period, NewAge, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company and defendants had no relationship with the military or FamilyMart; (2) the Company and defendants overstated the business agreements that they did have; (3) the Company and defendants never produced or sold a proprietary CBD beverage; (4) the Company lacked adequate internal controls; (5) as a result the Company had a heightened risk of regularly scrutiny and ultimately subject to an SEC investigation and action; and (6) as a result of the foregoing, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

International Business Machines Corporation (NYSE:IBM)

IBM Lawsuit on behalf of: investors who purchased January 18, 2018 - October 16, 2018
Lead Plaintiff Deadline: March 14, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ibm-class-action-submission-form?prid=35946&wire=1

According to the filed complaint, during the class period, International Business Machines Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue growth, CAMSS (the distinct components of "Cloud," "Analytics," "Mobile," "Security," and "Social") and CAMSS Components' revenue growth, and the Company's Segments' revenue growth were artificially inflated as a result of the wrongful reclassification/misclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; and (ii) IBM was materially less successful in growing its Strategic Imperative business, reporting materially higher growth than it actually achieved only by wrongfully reclassifying and misclassifying revenue from non-strategic to strategic thereby reporting publicly materially false Strategic Imperative Revenue.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/736807/CLASS-ACTION-UPDATE-for-SPPI-NBEVQ-and-IBM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Image for Press Release 1627419